Chunhui Han, PhD, discusses what biology-guided radiotherapy is and how it differs from traditional radiotherapy techniques.

Panelists discuss how managing extensive stage small cell lung cancer involves balancing the survival benefits of subsequent ...

Saeed Sadeghi, MD, discusses the differing mechanisms of action between luspatercept and epoetin alfa, highlighting how these ...

Panelists discuss how the first-line treatment landscape for metastatic renal cell carcinoma has evolved in recent years, ...

Panelists discuss how the combination of Tivozanib plus Nivolumab from the TiNivo-2 study, along with other data presented at ...

Panelists discuss how the CONTACT-02 study results reveal final overall survival data for patients with liver or bone ...

Panelists discuss how the EORTC-GUCG 1333 (PEACE-3) trial, presented at ESMO 2024, illuminates key findings regarding the ...

Saeed Sadeghi, MD, discusses the differing mechanisms of action between luspatercept and epoetin alfa, highlighting how these ...

Panelists discuss how bispecific antibodies are transforming the treatment landscape for non-Hodgkin lymphoma by enhancing T cell engagement and targeting malignant B cells effectively.

Hatim Husain, MD, discusses how acquired resistance to kinase inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC) poses a significant challenge in long-term treatment efficacy, necessitating ...

Dr. Leal discusses how the primary goals of therapy for patients with extensive stage small cell lung cancer (ES-SCLC) include balancing the potential survival benefits of subsequent treatment lines ...

Dr. Sabari discusses how, for extensive stage small cell lung cancer (ES-SCLC) that progresses within six months after platinum-based chemoimmunotherapy and immunotherapy maintenance, options like ...